Contributors |
|
xvii | |
|
Chapter 1 Overview of natural products in nutraceutical industries |
|
|
1 | (14) |
|
|
|
|
1 | (1) |
|
1.2 Global nutraceutical market |
|
|
2 | (2) |
|
1.3 Historical perspectives |
|
|
4 | (1) |
|
1.4 Status of natural products--derived nutraceuticals |
|
|
4 | (5) |
|
|
4 | (2) |
|
1.4.2 Dietary supplements |
|
|
6 | (2) |
|
|
8 | (1) |
|
|
8 | (1) |
|
|
8 | (1) |
|
|
9 | (1) |
|
1.5 Regulation of nutraceutical around the world |
|
|
9 | (1) |
|
1.6 Challenges and future perspectives |
|
|
10 | (1) |
|
|
10 | (5) |
|
|
11 | (4) |
|
|
15 | (16) |
|
|
|
|
|
|
|
15 | (1) |
|
2.2 Phytochemistry and isolation of bioactive components |
|
|
16 | (1) |
|
2.3 Hurdle of bioavailability and matrix design strategies for improving curcumin bioavailability |
|
|
17 | (1) |
|
2.4 Molecular targets of curcuminoids |
|
|
17 | (1) |
|
2.5 Curcuminoids in functional foods |
|
|
18 | (2) |
|
|
18 | (1) |
|
2.5.2 Dairy-based product |
|
|
19 | (1) |
|
2.5.3 Other functional foods |
|
|
19 | (1) |
|
2.6 Different formulations of curcuminoids and their role in nutraceuticals |
|
|
20 | (3) |
|
2.6.1 Inflammatory disorders |
|
|
20 | (1) |
|
|
21 | (1) |
|
2.6.3 Metabolic disorders |
|
|
22 | (1) |
|
2.6.4 Neurodegenerative disorders |
|
|
22 | (1) |
|
|
23 | (1) |
|
2.6.6 Other clinical indications |
|
|
23 | (1) |
|
|
23 | (8) |
|
|
23 | (8) |
|
Chapter 3 Boswellia serrata |
|
|
31 | (10) |
|
Ana Laura Tironi de Castilho |
|
|
Leonardo de Liori Teixeira |
|
|
Victor Antonio Costa Lima |
|
|
|
|
|
31 | (1) |
|
3.2 Use of B. serrata as a nutraceutical or functional food in neurological diseases |
|
|
32 | (2) |
|
3.3 Use of B. serrata as a nutraceutical or functional food in inflammatory diseases |
|
|
34 | (1) |
|
3.4 Use of B. serrata as a nutraceutical or functional food in gastrointestinal diseases |
|
|
35 | (1) |
|
3.5 Use of B. serrata as a nutraceutical or functional food with anticancer properties |
|
|
36 | (1) |
|
3.6 Use of B. serrata as a nutraceutical or functional food in the treatment of diabetes |
|
|
36 | (1) |
|
3.7 Use of B. serrata as a nutraceutical or functional food with antioxidant properties |
|
|
37 | (1) |
|
3.8 Use of B. serrata as a nutraceutical or functional food with antimicrobial properties |
|
|
37 | (1) |
|
3.9 Conclusion and perspectives |
|
|
37 | (4) |
|
|
38 | (3) |
|
Chapter 4 Role of Piper nigrum in functional food and nutraceuticals |
|
|
41 | (20) |
|
|
|
|
41 | (1) |
|
|
42 | (1) |
|
4.3 Nutritional and phytonutrient composition of black pepper |
|
|
42 | (1) |
|
4.4 Recommended dosage and quality specifications of P. nigrum |
|
|
43 | (2) |
|
4.5 Functional food and nutraceutical |
|
|
45 | (6) |
|
4.5.1 Antioxidant property of piper species and P. nigrum |
|
|
45 | (1) |
|
4.5.2 Anticancer property of piper species and P. nigrum |
|
|
46 | (1) |
|
4.5.3 Antiinflammatory property of piper species and P. nigrum |
|
|
47 | (1) |
|
4.5.4 Antimicrobial property of piper species and P. nigrum |
|
|
47 | (4) |
|
4.6 Other therapeutic benefits of P. nigrum |
|
|
51 | (1) |
|
4.6.1 P. nigrum for gastrointestinal health |
|
|
51 | (1) |
|
4.6.2 Antiobesity property of piper species and P. nigrum |
|
|
51 | (1) |
|
4.6.3 Anxiolytic and property of piper species and P. nigrum |
|
|
51 | (1) |
|
4.7 Uses of P. nigrum essential oil |
|
|
52 | (1) |
|
4.8 Culinary and ethnomedical uses of P. nigrum |
|
|
53 | (1) |
|
|
54 | (7) |
|
|
54 | (7) |
|
|
61 | (8) |
|
Ana Laura Tironi de Castilho |
|
|
Victor Antonio Costa Lima |
|
|
|
Leonardo de Liori Teixeira |
|
|
|
|
61 | (1) |
|
5.2 Beneficial effects from Ocimum sanctum as a nutraceutical or functional food |
|
|
62 | (4) |
|
5.3 Conclusion and future perspectives |
|
|
66 | (3) |
|
|
66 | (3) |
|
Chapter 6 Role of Moringa oleifera in nutraceuticals and functional foods |
|
|
69 | (26) |
|
|
|
|
|
|
Beatrice I.O. Ade-Omowaye |
|
|
|
69 | (1) |
|
6.2 Nutritional value of Moringa oleifera |
|
|
70 | (5) |
|
6.3 Traditional food and potential uses of Moringa oleifera |
|
|
75 | (1) |
|
6.4 Antimicrobial properties |
|
|
75 | (2) |
|
6.5 Anti-inflammatory properties |
|
|
77 | (1) |
|
6.6 Antioxidant properties |
|
|
78 | (2) |
|
6.7 Anticancer properties |
|
|
80 | (1) |
|
6.8 Antidiabetic properties |
|
|
81 | (1) |
|
6.9 Antiasthmatic properties |
|
|
82 | (1) |
|
6.10 Hepatoprotective properties |
|
|
83 | (1) |
|
6.11 Neuroprotective properties |
|
|
83 | (1) |
|
6.12 Conclusion and future directions |
|
|
84 | (11) |
|
|
84 | (11) |
|
Chapter 7 Galangal--Roles in nutraceuticals and functional foods |
|
|
95 | (16) |
|
|
|
|
|
7.1 Galangal and its phytochemistry |
|
|
95 | (3) |
|
7.2 Galangal in various formulations for different applications |
|
|
98 | (2) |
|
7.2.1 Galangal in various functional foods |
|
|
98 | (1) |
|
7.2.2 Galangal extracts as a packaging material |
|
|
99 | (1) |
|
7.3 Biological activities of galangal for different nutraceutical applications |
|
|
100 | (4) |
|
7.3.1 Anticancer activity |
|
|
100 | (1) |
|
7.3.2 Antiinflammatory agent |
|
|
101 | (1) |
|
7.3.3 Cardioprotective agent |
|
|
101 | (1) |
|
7.3.4 Antioxidant potential |
|
|
102 | (1) |
|
|
102 | (1) |
|
7.3.6 Neuroprotective and memory enhancing activity |
|
|
103 | (1) |
|
|
103 | (1) |
|
7.3.8 Antimicrobial activity |
|
|
103 | (1) |
|
|
104 | (1) |
|
|
104 | (1) |
|
7.4 Conclusion and future prospective |
|
|
104 | (7) |
|
|
105 | (6) |
|
Chapter 8 Bacopa monnieri |
|
|
111 | (22) |
|
|
|
|
111 | (1) |
|
|
112 | (1) |
|
8.3 Chemical constituents |
|
|
112 | (1) |
|
8.4 Extraction methods for chemical constituents |
|
|
113 | (1) |
|
8.5 Analytical techniques used for qualitative and quantitative analysis of B. monnieri |
|
|
113 | (2) |
|
8.6 Quantitative analysis of bacosides |
|
|
115 | (1) |
|
8.7 Structure elucidation of saponins in B. monnieri |
|
|
116 | (2) |
|
8.7.1 Infrared spectroscopy |
|
|
116 | (1) |
|
|
116 | (2) |
|
8.8 Biological activities |
|
|
118 | (1) |
|
|
118 | (1) |
|
8.10 Examples of standardized extract of B. monnieri as herbal formulations |
|
|
119 | (5) |
|
8.11 B. monnieri as a nutraceutical in commercial food products |
|
|
124 | (1) |
|
|
124 | (9) |
|
|
125 | (1) |
|
|
125 | (8) |
|
Chapter 9 Trigonella foenum graecum |
|
|
133 | (16) |
|
|
|
|
|
|
133 | (1) |
|
9.2 Morphology of fenugreek |
|
|
134 | (1) |
|
9.3 Chemical constituents |
|
|
135 | (2) |
|
9.3.1 Steroidal compounds and saponin |
|
|
135 | (1) |
|
|
135 | (1) |
|
|
136 | (1) |
|
|
136 | (1) |
|
9.3.5 Vitamins and minerals |
|
|
136 | (1) |
|
9.3.6 Lipids, fatty acids, and esters |
|
|
136 | (1) |
|
9.4 Roles of fenugreek as nutraceutical |
|
|
137 | (6) |
|
9.4.1 Anticancer property |
|
|
137 | (1) |
|
9.4.2 Antidiabetic activity |
|
|
138 | (1) |
|
|
138 | (1) |
|
9.4.4 Immunological activity |
|
|
139 | (1) |
|
9.4.5 Antiobesity activity |
|
|
139 | (1) |
|
9.4.6 Antibacterial and antifungal activity |
|
|
140 | (1) |
|
9.4.7 Antioxidant property |
|
|
141 | (1) |
|
9.4.8 Lowering and healing liver's hepatotoxicity and genotoxicity |
|
|
141 | (1) |
|
9.4.9 Anthelmintic activity |
|
|
141 | (1) |
|
9.4.10 Antiulcer property |
|
|
142 | (1) |
|
9.4.11 Rheumatoid arthritis |
|
|
142 | (1) |
|
9.4.12 Fenugreek in asthma treatment |
|
|
143 | (1) |
|
9.5 Fenugreek as functional food |
|
|
143 | (2) |
|
|
145 | (4) |
|
|
145 | (4) |
|
Chapter 10 Rosmarinus officinalis |
|
|
149 | (22) |
|
|
|
|
|
149 | (1) |
|
10.2 Rosemary oil and their roles in nutraceuticals and functional foods |
|
|
150 | (9) |
|
10.2.1 Effect of carnosic acid on improving oil stability and deep frying |
|
|
152 | (1) |
|
10.2.2 Rosemary as a potential source for increasing oil stability |
|
|
153 | (3) |
|
10.2.3 Effect of carnosic acid on improving shelf life and color of meat |
|
|
156 | (2) |
|
10.2.4 Effect of carnosic acid on stabilizing carotenoids like paprika (evidences) |
|
|
158 | (1) |
|
10.3 Effect of rosmarinic acid in beverage drinks |
|
|
159 | (2) |
|
10.3.1 Effect on shelf life extension |
|
|
159 | (1) |
|
10.3.2 Effect on color stability of beverages |
|
|
160 | (1) |
|
10.4 Effect of carnosic acid and rosmarinic acid on cognition |
|
|
161 | (1) |
|
10.5 Effect of ursolic acid |
|
|
162 | (2) |
|
10.5.1 Antimicrobial effect |
|
|
162 | (1) |
|
10.5.2 Immunity-enhancing effect |
|
|
162 | (1) |
|
10.5.3 Anticancerous activity of UA |
|
|
162 | (1) |
|
10.5.4 Antiobesity/Antidiabetic activity of UA |
|
|
163 | (1) |
|
10.5.5 Cardiovascular disease and effect of UA |
|
|
163 | (1) |
|
10.5.6 Brain function and effect of UA |
|
|
163 | (1) |
|
10.5.7 Liver diseases and effect of UA |
|
|
163 | (1) |
|
10.5.8 Improving exercise activity and effect of UA |
|
|
163 | (1) |
|
10.6 Conclusion and future perspectives |
|
|
164 | (7) |
|
|
164 | (6) |
|
|
170 | (1) |
|
Chapter 11 Phytochemicals and therapeutic potential of Punica granatum L |
|
|
171 | (40) |
|
|
|
|
|
171 | (1) |
|
11.2 Morphology of Punica granatum |
|
|
172 | (1) |
|
11.3 Nutritional and medicinal importance |
|
|
173 | (1) |
|
|
174 | (1) |
|
11.5 Phytochemicals present in various parts of pomegranate |
|
|
174 | (7) |
|
|
174 | (3) |
|
|
177 | (1) |
|
|
177 | (1) |
|
|
178 | (1) |
|
11.5.5 Pomegranate flower |
|
|
179 | (1) |
|
|
179 | (2) |
|
11.6 Pharmacological activities of pomegranate |
|
|
181 | (10) |
|
11.6.1 Anticancer activity |
|
|
181 | (1) |
|
11.6.2 Neuroprotective activity |
|
|
182 | (1) |
|
11.6.3 Antioxidant activity |
|
|
183 | (2) |
|
11.6.4 Lipid-lowering activity |
|
|
185 | (1) |
|
11.6.5 Antibacterial activity |
|
|
185 | (1) |
|
11.6.6 Antiviral activity |
|
|
185 | (1) |
|
11.6.7 Antileishmanial and anticoccidial activity |
|
|
186 | (1) |
|
11.6.8 Antiinflammatory activity |
|
|
186 | (2) |
|
11.6.9 Antidiabetic activity |
|
|
188 | (1) |
|
11.6.10 Pregnancy complication treatment |
|
|
189 | (1) |
|
11.6.11 Antilice and antidandruff activity |
|
|
189 | (1) |
|
11.6.12 Antiacnes activity |
|
|
189 | (1) |
|
11.6.13 Nephroprotective activity |
|
|
190 | (1) |
|
11.6.14 Cardioprotective activity |
|
|
190 | (1) |
|
11.6.15 Hepatoprotective activity |
|
|
190 | (1) |
|
11.6.16 Miscellaneous activities |
|
|
190 | (1) |
|
11.7 Role of phytoconstituents in the management of environment pollutant |
|
|
191 | (1) |
|
11.8 Applications of P. granatum in nanotechnology |
|
|
192 | (1) |
|
11.9 Industrial uses of pomegranate |
|
|
192 | (1) |
|
11.10 Patents granted on P. granatum |
|
|
193 | (3) |
|
11.11 Pomegranate in clinical trials |
|
|
196 | (1) |
|
11.12 Toxicity of pomegranate |
|
|
197 | (1) |
|
|
197 | (14) |
|
|
198 | (13) |
|
|
199 | (12) |
|
Chapter 12 Garcinia cambogia |
|
|
211 | (8) |
|
|
|
|
|
211 | (1) |
|
12.2 Phytochemical analysis |
|
|
211 | (1) |
|
|
212 | (1) |
|
12.4 Pharmacological activities and mechanism of action |
|
|
213 | (1) |
|
|
214 | (1) |
|
|
215 | (4) |
|
|
215 | (1) |
|
|
216 | (3) |
|
Chapter 13 Camellia sinensis |
|
|
219 | (14) |
|
|
|
219 | (1) |
|
|
219 | (2) |
|
|
221 | (1) |
|
13.4 Pharmacological activities |
|
|
221 | (5) |
|
13.4.1 Antioxidant activity |
|
|
221 | (1) |
|
13.4.2 Anticancer activity |
|
|
222 | (1) |
|
13.4.3 Antibacterial activity |
|
|
223 | (1) |
|
13.4.4 Antiviral activity |
|
|
223 | (1) |
|
13.4.5 Antiobesity activity |
|
|
224 | (1) |
|
13.4.6 Antimicrobial activity |
|
|
224 | (1) |
|
13.4.7 Antihypertensive and cardiovascular activity |
|
|
225 | (1) |
|
13.4.8 Other promising activities |
|
|
225 | (1) |
|
|
226 | (7) |
|
|
226 | (7) |
|
Chapter 14 Ferula asafoetida |
|
|
233 | (12) |
|
|
|
|
|
233 | (1) |
|
14.2 Chemical constituents |
|
|
233 | (1) |
|
14.3 Pharmacological and therapeutic potentials of asafoetida |
|
|
234 | (5) |
|
14.3.1 Anticancer activity |
|
|
234 | (1) |
|
14.3.2 Neuroprotective effects |
|
|
235 | (1) |
|
14.3.3 Effect on the gastrointestinal tract |
|
|
236 | (1) |
|
14.3.4 Relaxant and antispasmodic effects |
|
|
236 | (1) |
|
14.3.5 Hepatoprotective effect |
|
|
237 | (1) |
|
14.3.6 Antimicrobial activity |
|
|
237 | (1) |
|
14.3.7 Antiparasitic activity |
|
|
238 | (1) |
|
14.3.8 Antidiabetic and anti-obesity effects |
|
|
238 | (1) |
|
14.3.9 Effect on blood and blood vessels |
|
|
239 | (1) |
|
14.3.10 Metabolic activity |
|
|
239 | (1) |
|
14.3.11 Anti-aging effect |
|
|
239 | (1) |
|
14.3.12 Reproductive effects |
|
|
239 | (1) |
|
|
239 | (1) |
|
|
240 | (5) |
|
|
240 | (5) |
|
Chapter 15 Concise review on Asparagus racemosus and its role as nutraceuticals and functional foods |
|
|
245 | (12) |
|
|
|
|
|
245 | (2) |
|
|
247 | (1) |
|
15.3 Macroscopic and microscopic characterization |
|
|
247 | (1) |
|
15.3.1 Macroscopic characterization |
|
|
247 | (1) |
|
15.3.2 Microscopic characterization |
|
|
247 | (1) |
|
15.4 Cultivation of Asparagus racemosus |
|
|
247 | (1) |
|
15.5 Nutritional and traditional medicinal value of Asparagus racemosus |
|
|
248 | (1) |
|
|
248 | (1) |
|
15.5.2 Local food and other uses |
|
|
248 | (1) |
|
15.6 Pharmacological activities |
|
|
248 | (3) |
|
15.6.1 Antidiarrheal and antiulcer effects |
|
|
248 | (1) |
|
15.6.2 Galactagogue effects |
|
|
249 | (1) |
|
15.6.3 Phytoestrogenic effects |
|
|
249 | (1) |
|
15.6.4 Antimicrobial effects |
|
|
249 | (1) |
|
15.6.5 Antiepileptic and neuroprotective effects |
|
|
250 | (1) |
|
15.6.6 Immunomodulatory and immunoadjuvant effects |
|
|
250 | (1) |
|
15.6.7 Antidiabetic activities |
|
|
250 | (1) |
|
15.6.8 Lithiatic activity |
|
|
250 | (1) |
|
15.7 Chemical constituents |
|
|
251 | (1) |
|
|
252 | (1) |
|
15.9 Adverse effect and precaution |
|
|
252 | (5) |
|
|
252 | (5) |
|
Chapter 16 Cinnamon as a potential nutraceutical and functional food ingredient |
|
|
257 | (22) |
|
|
|
|
257 | (1) |
|
|
258 | (1) |
|
16.3 Composition of cinnamon |
|
|
259 | (1) |
|
16.4 Natural compounds of cinnamon and therapeutic uses |
|
|
260 | (7) |
|
16.4.1 Antioxidant activity of cinnamon |
|
|
262 | (1) |
|
16.4.2 Antidiabetic activity |
|
|
263 | (2) |
|
16.4.3 Antiinflammatory activity |
|
|
265 | (1) |
|
16.4.4 Antibacterial activity |
|
|
265 | (1) |
|
16.4.5 Anticancer activity |
|
|
266 | (1) |
|
16.5 Other therapeutic benefits |
|
|
267 | (1) |
|
16.5.1 Antiulcer and gastric effect |
|
|
267 | (1) |
|
16.5.2 Alzheimer's disease |
|
|
267 | (1) |
|
16.5.3 Parkinson's disease |
|
|
267 | (1) |
|
16.5.4 Cardiovascular diseases and cancer |
|
|
267 | (1) |
|
16.6 Advanced glycation end products |
|
|
268 | (1) |
|
16.7 Culinary uses of cinnamon across the globe |
|
|
268 | (1) |
|
|
269 | (10) |
|
|
269 | (10) |
|
Chapter 17 Myristica fragrans (Houtt) |
|
|
279 | (30) |
|
Arya Kadukkattil Ramanunny |
|
|
|
|
Jithu Nambukulangara Vijayan |
|
|
|
279 | (1) |
|
|
280 | (1) |
|
17.3 Morphology and pharmacognostical details of M. fragrans fruit |
|
|
280 | (1) |
|
17.4 Estimation of composition in rind, nutmeg, and mace |
|
|
281 | (1) |
|
17.5 Phytochemistry of M. fragrans fruit |
|
|
281 | (6) |
|
17.5.1 Phenolic compounds |
|
|
283 | (1) |
|
|
283 | (4) |
|
17.6 Extraction and analysis of bioactive components from M. fragrans |
|
|
287 | (1) |
|
17.7 Application of M. fragrans |
|
|
288 | (12) |
|
17.7.1 Source of nutrition |
|
|
289 | (1) |
|
17.7.2 Culinary and HORECA products |
|
|
290 | (1) |
|
17.7.3 Therapeutic benefits |
|
|
291 | (9) |
|
17.8 Focus on future perspective of nutmeg |
|
|
300 | (1) |
|
17.9 Toxicity aspects of M. fragrans |
|
|
301 | (1) |
|
|
302 | (7) |
|
|
302 | (7) |
|
Chapter 18 "Ashtawarga": the wonder medicinal herbs of nature |
|
|
309 | (28) |
|
|
|
|
|
|
|
309 | (1) |
|
|
309 | (1) |
|
18.3 Lack of standardization of Ashtawarga plants |
|
|
310 | (9) |
|
18.3.1 Steps taken toward standardization |
|
|
314 | (1) |
|
18.3.2 Scientific basis of pairing between Ashtawarga plants |
|
|
315 | (4) |
|
18.4 Uses of Ashtawarga plants in traditional and modern system of medicine |
|
|
319 | (9) |
|
18.5 Red list category and criteria |
|
|
328 | (2) |
|
18.6 Conservation actions and strategies for future prospects |
|
|
330 | (7) |
|
|
330 | (6) |
|
|
336 | (1) |
|
Chapter 19 Regulatory aspects of nutraceuticals |
|
|
337 | (10) |
|
|
|
|
|
337 | (1) |
|
19.2 Need for regulatory standards |
|
|
338 | (1) |
|
19.3 Overview on different regulatory bodies |
|
|
338 | (5) |
|
19.3.1 Regulation in the United States of America |
|
|
338 | (1) |
|
19.3.2 Regulation in Canada |
|
|
339 | (1) |
|
19.3.3 Regulatory aspects in Australia and New Zealand |
|
|
339 | (1) |
|
19.3.4 Regulations in China |
|
|
340 | (1) |
|
19.3.5 Regulations in Japan |
|
|
340 | (1) |
|
19.3.6 Regulation in the European Union |
|
|
341 | (1) |
|
19.3.7 Regulation in the Association of South East Asian Nation region |
|
|
342 | (1) |
|
19.3.8 Regulation in India |
|
|
343 | (1) |
|
|
343 | (4) |
|
|
344 | (3) |
|
Chapter 20 Current trends and technologies in nutraceutical industry |
|
|
347 | (14) |
|
|
|
347 | (1) |
|
20.2 Current trends to drive nutraceutical industry: global scenario |
|
|
347 | (5) |
|
20.2.1 Rise of noncommunicable diseases |
|
|
348 | (3) |
|
20.2.2 High health-care cost |
|
|
351 | (1) |
|
20.2.3 High personnel income, change of lifestyle, thinking pattern of the people, and use of nutraceuticals as medicines |
|
|
351 | (1) |
|
20.2.4 Misbelief toward conventional medicines |
|
|
352 | (1) |
|
20.2.5 Demand for the convenience |
|
|
352 | (1) |
|
20.3 Technologies in nutraceutical industry |
|
|
352 | (9) |
|
|
358 | (3) |
|
Chapter 21 Future prospective of nutraceutical and functional food with herbs and spices |
|
|
361 | (22) |
|
|
|
|
|
|
|
361 | (2) |
|
21.2 Traditional nutraceuticals and products |
|
|
363 | (6) |
|
|
363 | (1) |
|
|
364 | (3) |
|
21.2.3 Difference between nutraceuticals and functional foods |
|
|
367 | (2) |
|
21.3 Health benefits of nutraceuticals and functional foods |
|
|
369 | (1) |
|
21.4 The global nutraceuticals and functional foods market |
|
|
369 | (1) |
|
21.5 Motivators of nutraceutical and functional foods market |
|
|
370 | (1) |
|
21.6 Present status of nutraceutical and functional foods |
|
|
371 | (2) |
|
|
371 | (1) |
|
|
372 | (1) |
|
|
372 | (1) |
|
|
372 | (1) |
|
21.7 Challenges in the nutraceuticals and functional foods market |
|
|
373 | (1) |
|
21.8 Regulatory and perception issues |
|
|
373 | (1) |
|
21.9 A snapshot of global regulations |
|
|
374 | (1) |
|
|
374 | (1) |
|
|
374 | (1) |
|
|
375 | (1) |
|
|
375 | (1) |
|
|
375 | (1) |
|
21.10 Toxicity potential of nutraceuticals and functional foods |
|
|
375 | (1) |
|
21.11 Future prospects of nutraceuticals and functional foods |
|
|
375 | (1) |
|
21.12 Nutraceuticals/functional foods: the future of intelligent food |
|
|
376 | (1) |
|
21.13 Characteristics of success: daring to win |
|
|
377 | (1) |
|
|
377 | (1) |
|
21.13.2 Compliant marketing |
|
|
377 | (1) |
|
|
377 | (1) |
|
|
378 | (1) |
|
|
378 | (1) |
|
|
378 | (1) |
|
|
378 | (5) |
|
|
379 | (2) |
|
|
381 | (2) |
Index |
|
383 | |